Clinical Focus

  • Internal Medicine

Academic Appointments

Professional Education

  • Medical Education: Rush Medical College (05/31/2020) IL
  • Residency: Kaiser Permanente Santa Clara Internal Medicine Residency (06/30/2023) CA
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2023)
  • Residency: Kaiser Permanente Santa Clara Internal Medicine Residency (2023) CA
  • Medical Education: Rush Medical College (2020) IL

Contact

  • Academic
    stinalin@stanford.edu
    University - Other Teaching/Research Department: Medicine - Med/Gastroenterology and Hepatology Position: Instructor
  • Clinical (Primary)  Stanford Gastroenterology and Liver Transplant 500 Pasteur Dr Stanford, CA 94304 (650) 723-9178 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 6341

All Publications

  • Serum gastrin levels are associated with prevalent neuroendocrine tumors in autoimmune metaplastic atrophic gastritis. The American journal of gastroenterology Jove, A., Lin, C., Hwang, J. H., Vidhya, B., Fernandez-Becker, N. Q., Huang, R. J. 2024

    Abstract

    Autoimmune metaplastic atrophic gastritis (AMAG) is a precancerous condition that predisposes to gastric neuroendocrine tumors (gNET). There exist no methods to stratify AMAG patients for gNET risk.We identified a cohort of patients with AMAG within a university health system using histopathologic and serologic criteria. We analyzed features predictive of prevalent gNET.We identified 181 AMAG patients, 41 (22.7%) with prevalent gNET. Gastrin levels were elevated in gNET (1859.8 versus 679.5 pg/mL, p<0.001), and gastrin titers demonstrated good discrimination (c=0.799, 95% CI 0.707-0.892) for gNET.Gastrin levels differ significantly between AMAG patients with and without gNET.

    View details for DOI 10.14309/ajg.0000000000003235

    View details for PubMedID 39588964

  • Serologic Features of Autoimmune Metaplastic Atrophic Gastritis: Gastrin Level as a Predictor of Gastric Neuroendocrine Tumor Status Jove, A. G., Lin, C., Hwang, J., Balasubramanian, V., Fernandez-Becker, N., Huang, R. LIPPINCOTT WILLIAMS & WILKINS. 2024: S1643-S1644

    View details for DOI 10.14309/01.ajg.0001038532.32643.7b

    View details for Web of Science ID 001359314900015

  • Risk of Gastric and Small Intestinal Cancer in Patients With Lynch syndrome - Data From a Large, Community-Based U.S. Population. Clinical and translational gastroenterology Lin, C. F., Carwana, H. E., Jiang, S. F., Li, D. 2024

    Abstract

    Risk of gastric and small intestinal cancer in Lynch syndrome (LS) remains poorly understood. We investigated the risk of gastric and small intestinal cancer in patients with LS in a large, community-based population.This retrospective cohort study included all patients diagnosed with LS between 1/1/1997-12/31/2020 at Kaiser Permanente Northern California. Cumulative incidence of gastric cancer and small intestinal cancer was calculated using competing risk methodology.Among 1106 LS patients with a median follow-up of 19.3 years (interquartile range [IQR] 9.4-24.0 years), 11 developed gastric cancer (8 MSH2, 2 MLH1 and 1 PMS2) with the median diagnosis age of 56 years (IQR 42-63 years); 11 developed small intestinal cancer (6 MSH2, 3 MLH1, 1 MSH6 and 1 PMS2) with the median diagnosis age of 57 years (IQR 50-66 years). Cumulative incidence by age 80 years was 7.26% (95% confidence internal [CI], 1.80-18.03%) for men and 3.43% (95% CI, 0.50-11.71%) for women for gastric cancer, and was 7.28% (95% CI, 3.19-13.63%) for men and 2.21% (95% CI, 0.23-9.19%) for women for small intestinal cancer. Pathogenic variants (PV) carriers of MSH2 and MLH1 had the highest risk of gastric and small intestinal cancer. History of Helicobacter pylori (H. pylori) infection was associated with increased risk of gastric cancer (adjusted odds ratio 5.52; 95% CI, 1.72-17.75).Patients with LS, particularly MSH2 and MLH1 PV carriers, had significantly increased lifetime risk of gastric and small intestinal cancer. Testing and treatment of H. pylori should be considered for all patients with LS.

    View details for DOI 10.14309/ctg.0000000000000739

    View details for PubMedID 38920292

  • CLINICAL AND SEROLOGIC FEATURES OF AUTOIMMUNE METAPLASTIC ATROPHIC GASTRITIS: RESULTS OF AN ELECTRONIC HEALTH RECORDS COHORT Jove, A., Lin, C., Hwang, J., Fernandez-Becker, N., Huang, R. MOSBY-ELSEVIER. 2024: AB1095-AB1096

    View details for Web of Science ID 001278323004222